<DOC>
	<DOC>NCT00594386</DOC>
	<brief_summary>The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the Rotigotine patch in subjects with advanced-stage idiopathic Parkinson's Disease.</brief_summary>
	<brief_title>An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease</brief_title>
	<detailed_description>This is the open-label extension to the randomized, double-blind, placebo-controlled SP650 trial that assessed the efficacy and safety and tolerability of the Rotigotine patch in subjects with advanced-stage idiopathic Parkinson's Disease who are not well-controlled on Levodopa.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Subjects who have completed six months of maintenance treatment in the SP650 doubleblind trial Subjects who had an ongoing serious adverse event from the SP650 doubleblind trial that was assessed as related to study medication</criteria>
	<gender>All</gender>
	<minimum_age>31 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Neupro</keyword>
</DOC>